195 related articles for article (PubMed ID: 12893027)
1. Anti-thrombotic activity of PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats.
Tang Z; Wang Y; Xiao Y; Zhao M; Peng S
Thromb Res; 2003 May; 110(2-3):127-33. PubMed ID: 12893027
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet aggregation by polyaspartoyl L-arginine and its mechanism.
Wang YY; Tang ZY; Dong M; Liu XY; Peng SQ
Acta Pharmacol Sin; 2004 Apr; 25(4):469-73. PubMed ID: 15066215
[TBL] [Abstract][Full Text] [Related]
3. Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio--venous shunt thrombosis in vivo.
Tohti I; Tursun M; Umar A; Turdi S; Imin H; Moore N
Thromb Res; 2006; 118(6):733-9. PubMed ID: 16469363
[TBL] [Abstract][Full Text] [Related]
4. Anti-thrombotic efficacy of S007-867: Pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro.
Misra A; Prakash P; Aggarwal H; Dhankani P; Kumar S; Pandey CP; Pugh N; Bihan D; Barthwal MK; Farndale RW; Dikshit DK; Dikshit M
Biochem Pharmacol; 2018 Feb; 148():288-297. PubMed ID: 29309758
[TBL] [Abstract][Full Text] [Related]
5. Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats.
Sudo T; Ito H; Hayashi H; Nagamura Y; Toga K; Yamada Y
Thromb Haemost; 2007 Apr; 97(4):665-72. PubMed ID: 17393031
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic activity of a newly synthesized coumarin derivative 3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide.
Jain M; Surin WR; Misra A; Prakash P; Singh V; Khanna V; Kumar S; Siddiqui HH; Raj K; Barthwal MK; Dikshit M
Chem Biol Drug Des; 2013 Apr; 81(4):499-508. PubMed ID: 23534412
[TBL] [Abstract][Full Text] [Related]
7. Polyaspartoyl.l-arginine inhibits platelet aggregation through stimulation of NO release from endothelial cells.
Tang Z; Zhao M; Li C; Wang Y; Peng S
Eur J Pharmacol; 2008 Jun; 588(1):41-6. PubMed ID: 18457831
[TBL] [Abstract][Full Text] [Related]
8. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative.
Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP
Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
Kim CW; Yun JW; Bae IH; Park YH; Jeong YS; Park JW; Chung JH; Park YH; Lim KM
Thromb Res; 2011 Jun; 127(6):565-70. PubMed ID: 21420150
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
[TBL] [Abstract][Full Text] [Related]
12. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
13. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of anti-thrombotic activity of benzocoumarin amide derivatives.
Sashidhara KV; Palnati GR; Avula SR; Singh S; Jain M; Dikshit M
Bioorg Med Chem Lett; 2012 May; 22(9):3115-21. PubMed ID: 22483393
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
17. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.
Wang YX; Vincelette J; da Cunha V; Martin-McNulty B; Mallari C; Fitch RM; Alexander S; Islam I; Buckman BO; Yuan S; Post JM; Subramanyam B; Vergona R; Sullivan ME; Dole WP; Morser J; Bryant J
Thromb Haemost; 2007 May; 97(5):847-55. PubMed ID: 17479197
[TBL] [Abstract][Full Text] [Related]
18. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
Xu HL; Feng YP
Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
[TBL] [Abstract][Full Text] [Related]
19. Polyaspartoyl l-arginine protects endothelial cells against injury.
Jian Y; Tang Z; Wang Y; Peng S
Eur J Pharmacol; 2008 Dec; 599(1-3):96-101. PubMed ID: 18854183
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis.
Lockyer S; Kambayashi J
J Cardiovasc Pharmacol; 1999 May; 33(5):718-25. PubMed ID: 10226858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
